The CJC-1295 and Ipamorelin combination pen contains two distinct growth hormone-releasing research peptides supplied as a single pre-filled formulation. CJC-1295 is a synthetic GHRH analogue and Ipamorelin is a selective ghrelin receptor agonist (growth hormone secretagogue). The two peptides have complementary mechanisms in research models, and verification must confirm purity of both compounds independently. The Certificate of Analysis on this page documents in-house HPLC verification of the combined formulation at the time of fill.
In-House Testing
BodyPharm laboratory
- Report
- #260114
- Batch
- CJIP9837
- Purity (HPLC)
- 99.09%
- Concentration
- 5.2 mg/ml
Testing Methodology
In-House HPLC Verification
BodyPharm in-house report #260114 documents Reverse-Phase HPLC analysis of batch CJIP9837 at 99.09% purity, with combined concentration of 5.2 mg/ml in the pen formulation. CJC-1295 (modified GHRH 1-29) and Ipamorelin (a synthetic pentapeptide) have distinct retention behaviour on RP-HPLC and resolve as separable peaks on a standard C18 column. Per-batch testing is repeated for every production run with a unique report number to support full batch traceability through manufacture, fill, and dispatch.
DAC vs Non-DAC CJC-1295
BodyPharm CJC-1295 in this combination is the Non-DAC variant (without Drug Affinity Complex), which has a half-life of approximately 30 minutes and produces a pulsatile pattern of growth hormone release in research models. This contrasts with DAC-modified CJC-1295, which has a half-life of approximately 8 days due to albumin conjugation. The COA explicitly identifies the CJC-1295 variant in the combination so researchers can match material to the published literature relevant to their experimental design.
Stack Ratio Verification
The two peptides are filled at a research-typical 1:1 mass ratio, with the integration ratio between peaks on the chromatogram confirming both compounds are present in the documented blend. Ipamorelin is a smaller peptide (5 residues) than CJC-1295 (29 residues), so molar ratios differ from mass ratios. Researchers calculating molar dosing for receptor-binding studies should reference both molecular weights when interpreting concentration values from the COA.
What This Result Means for Researchers
CJC-1295 and Ipamorelin are studied together because they target distinct points in the growth hormone axis: CJC-1295 binds the GHRH receptor on pituitary somatotrophs, while Ipamorelin binds the ghrelin receptor (GHSR-1a). Research suggests this combined receptor engagement produces a more pronounced growth hormone pulse than either compound alone, particularly in models examining GH axis pulsatility versus sustained release. Ipamorelin is notable for its selectivity: research indicates it does not significantly stimulate cortisol or prolactin release at concentrations producing GH effects, distinguishing it from older growth hormone secretagogues. The combination is investigated in models of GH axis regulation, IGF-1 downstream signalling, and somatopause-related research.
Frequently Asked Questions
Related Products
CJC1295 & Ipamorelin 20 Pen
CJC-1295 and Ipamorelin 20mg combination pen with HPLC-verified purity at 99.09%.